Syndax Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SNDX | RCUS | AVBP | VSTM | AGMB | RLAY | |
|---|---|---|---|---|---|---|
| Market cap | 940.80M | 2.43B | 665.16M | 1.20B | 337.35M | 3.95B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -14.4 | -6.2 | -3.6 | -8.1 | -3.4 | -11.0 |
| Price/book | -54.7 | 3.8 | 1.8 | 17.8 | 2.7 | 5.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −28.86% | −1.28% | −26.64% | +24.21% | −53.24% | +176.11% |
| Today | −26.87% | +2.12% | +3.61% | +0.82% | 0.00% | +3.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SNDX news ›Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
Syndax Pharmaceuticals shows strong Revuforj-driven growth, narrowing losses, and AML upside. Read the latest analysis on SNDX stock here. - Syndax Pharmaceuticals remains on track, with Revuforj driving robust commercial growth and…
Synlogic (SYBX) Projected to Post Earnings on Wednesday
Posted by Danessa Lincoln on Nov 4th, 2026 Synlogic (NASDAQ:SYBX – Get Free Report) will likely be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($5.80) per share for the…
Syndax Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
(NASDAQ:SNDX) 2026-11-04 Seeking Alpha The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-11-02 Earnings Summary
More from 1 other outlet
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 9.7% - Still a Buy?
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was up 9.7% during mid-day trading on Tuesday. The company traded as high as $14.43 and last traded at $14.37. 1,495,421 shares changed hands during mid-day trading, a decline of…
Syndax Q3 Revenue Hits $83.3 Million on Drug Growth
Syndax Pharmaceuticals Inc. (SNDX) reported a sharp increase in third-quarter 2026 revenue as Revuforj prescriptions continued to grow and its share of Niktimvo commercial profit increased. Total revenue reached $83.3 million, up from…
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS
Posted by Sarita Garza on Nov 3rd, 2026 Here are the key takeaways from Syndax Pharmaceuticals’ conference call: Here are the key news stories impacting Syndax Pharmaceuticals this week: View Our Latest Analysis on Syndax Pharmaceuticals…
Syndax anticipates Revuforj could exceed $2B in U.S. peak annual net revenue as post-transplant maintenance builds
Syndax Q3 2026 earnings: Revuforj and Niktimvo drove strong revenue growth, with 2027 catalysts ahead. Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q3 2026 - “Syndax delivered another strong quarter of commercial growth and…
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
- Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase - - Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia; 20% q/q growth in…
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
Posted by Michael Walen on Nov 3rd, 2026 Syndax Pharmaceuticals (NASDAQ:SNDX) reported third-quarter 2026 total revenue of $83.3 million, an 82% increase from the prior-year period, as sales of its Revuforj leukemia treatment and…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ: SNDX). Such... NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com4
- themarketsdaily.com3
- defenseworld.net2
- marketbeat.com2
- tradingview.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.